CTAD ASIA 2027
Keynote Speakers
Meet the leading experts who will share the latest advances in brain health, Alzheimer's disease research and therapeutic strategies.
KEYNOTE
Lifestyle and Brain Health:
What Does the Evidence Tell Us in 2027?
Sandrine Andrieu, MD, PhD
Professor of Public Health, Chair of the Clinical Epidemiology and Public Health Department, IHU HealthAge, Toulouse (France), and Adjunct Professor at the University of New Mexico (USA).
Sandrine Andrieu is a physician and professor of public health, chair of the Clinical Epidemiology and Public Health Department at Toulouse University Hospital and adjunct professor at the University of New Mexico (USA).
Since 2009, she has been responsible for the aging research team at the Center for Epidemiology and Research in Population Health. She served as director of the research center for Epidemiology and Research in Population Health (formerly UMR1027; CERPOP UMR1295 Inserm) from 2011 to 2020. She has published more than 300 international papers and book chapters in the field of aging. She was involved in large prevention studies in the field of neurodegenerative disease (GuidAge, MAPT) and in European projects including HATICE, MIND-AD and PRODEMOS. Her main research focus is the prevention of age-related loss of function and healthy aging. She is the past president of the French National Society of Geriatrics and Gerontology. As a member of IHU HealthAge, she is responsible for large preventive trials.
KEYNOTE
Alzheimer's Disease:
Emerging Therapeutics and Evolving Strategies
Jeffrey Cummings, MD
Joy Chambers-Grundy Professor of Brain Science, Director of the Chambers-Grundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States).
UNLV research professor Jeffrey L. Cummings is a neurologist globally recognized for his contributions to Alzheimer's research, drug development, and clinical trials. He serves as the Joy Chambers-Grundy Professor of Brain Science and Director of the Chambers-Grundy Center for Transformative Neuroscience at the Kirk Kerkorian School of Medicine's Department of Brain Health.
Dr. Cummings leads the UNLV Clinical Trials Observatory, the world’s only research observatory devoted exclusively to analyzing the pipeline of Alzheimer's drugs in clinical trials to better inform drug development decisions. He also heads a biomarker observatory, which captures and categorizes emerging information on blood tests, brain scans, and digital devices related to Alzheimer's disease.
Prior to joining UNLV in 2019, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, as well as two UCLA entities: the Mary S. Easton Center for Alzheimer’s Disease Research and the Deane F. Johnson Center for Neurotherapeutics.
Named a “Rock Star of Science” by Gentleman’s Quarterly, Dr. Cummings, a fellow of the American Association for the Advancement of Science, has published 43 books and more than 900 peer-reviewed articles on neuropsychiatry, Alzheimer’s disease, and clinical trials.
His numerous recognitions for scientific and leadership contributions include the American Association of Geriatric Psychiatry’s Distinguished Scientist Award, the Melvin R. Goodes Prize for Excellence in Drug Development from the Alzheimer's Drug Discovery Foundation, the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award, and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award. In 2024, he was ranked by ScholarGPS as the world's top scholar for his lifetime contributions in the areas of dementia and drug development.
|